Monitoring Visit Checklist
Monitoring Visit Checklist
Quick Reference Tool | PsychHQ Source: Module 9, Monitoring, Adjusting & Long-Term Management | Last Updated: February 2026
Why Monitoring Matters
The MTA study demonstrated that structured monitoring, not the medication itself, drove the difference in outcomes. The community care arm received the same drugs but with less systematic follow-up and produced significantly worse results (MTA Cooperative Group, 1999). Treatment persistence in pediatric ADHD averages only 170 days (EAGG, 2024), and fewer than 25% maintain consistent daily adherence at 12 months. Every follow-up visit is an adherence rescue intervention.
Monitoring Intervals Across Major Guidelines
| Parameter | AAP (2019) | NICE NG87 (2018/2024) | CADDRA (4th Ed., 2020) | AADPA (2022) |
|---|---|---|---|---|
| Titration visits | Every 2-4 weeks | At every dose change (HR/BP required) | Frequent until stable | Every 2-4 weeks |
| Maintenance visits | Every 3-6 months | Every 3-6 months | Individualized | Every 3-6 months |
| Height (pediatric) | "Regularly" (at well-child visits) | Every 6 months, plotted on growth chart | At every visit until stable | Every 6 months |
| Weight (pediatric) | "Regularly" | Every 3 months (age 10 and under); every 6 months (over 10) | At every visit until stable | Every 6 months |
| HR and BP | At every visit | At every dose change; every 6 months minimum | At every visit | At every visit |
| Rating scales | At baseline; periodically | At baseline; annual review | At baseline; every visit until stable | At baseline; annually |
| Comprehensive review | Implied in ongoing management | Annually (strongly recommended) | Annually recommended | Annually |
| Functional assessment | Emphasized but not operationalized | Included in annual review | WFIRS recommended | Emphasized as primary outcome |
Prescribing note: For Schedule II stimulant prescriptions, prescribers are generally required to see patients at minimum every 90 days (every 3 months) for ongoing maintenance. State regulations may vary, but this cadence is a practical minimum for responsible controlled substance management, even in stable patients.
The 4-Minute Monitoring Workflow
For time-limited settings, this is the minimum structured monitoring workflow that adds structure without adding length:
| Step | Who | What | Time |
|---|---|---|---|
| 1 | MA/Nurse | Height, weight, BP, HR recorded during rooming | Part of vitals |
| 2 | Parent/Patient | Complete a brief symptom tracking scale (Vanderbilt follow-up form, SNAP-IV, or ADHD-RS, not a full diagnostic Vanderbilt each time) in waiting room or via portal before the visit | ~5 min (pre-visit) |
| 3 | Clinician | Compare today's rating scale score to last visit: trending better, stable, or worse? | 30 sec |
| 4 | Clinician | Three side-effect questions: "How's sleep? How's appetite? Any mood changes?" | 1 min |
| 5 | Clinician | One functional question: "How are grades/work/relationships?" | 1 min |
| 6 | Clinician | Pediatric: confirm growth is plotted on chart | 30 sec |
| 7 | Clinician | Document, compare to trajectory, adjust plan if needed | 1 min |
Total added clinician time: ~4 minutes beyond a standard refill visit.
Five-Domain Maintenance Assessment
At every maintenance visit, five domains warrant structured assessment:
1. Symptom Status
Use the same validated rating scale used at baseline (consistency allows direct score comparisons over time).
| Instrument | Best For | Key Feature |
|---|---|---|
| Vanderbilt (VADRS) | Primary care screening and monitoring | Free; includes comorbidity subscales (ODD, CD, anxiety); follow-up forms with side effect tracking |
| SNAP-IV | Titration phase tracking | Free; highly sensitive to medication-induced change; DSM symptom mapping |
| ADHD-RS-IV/5 | Setting response/remission targets | Clinical trial gold standard; precise psychometric benchmarks |
| ASRS-5 | Adult screening and monitoring | Updated psychometrics for inattentive presentation |
2. Side Effects
Use a structured inventory at every visit. Key domains to screen:
| Domain | What to Ask |
|---|---|
| Appetite | "How is appetite? Is lunch being eaten? Has weight changed?" |
| Sleep | "How long to fall asleep? What time? Any middle-of-night waking?" |
| Mood/Emotional blunting | "Any mood changes? Feeling flat or emotionally dulled? More tearful or irritable?" |
| Headache/GI | "Any headaches or stomachaches?" |
| Tics | "Any new movements or sounds?" |
| Cardiovascular | "Any chest pain, palpitations, dizziness, or fainting?" |
| Adolescents | Add: sexual side effects (SSRI context) |
3. Growth Parameters (Pediatric)
Plot height, weight, and BMI on a standardized growth chart at every visit.
Red-Flag Thresholds Triggering Active Management:
| Parameter | Red-Flag Threshold | Action |
|---|---|---|
| Height velocity | Below 4 cm/year in mid-childhood (ages 6-12) | Initiate growth management hierarchy |
| Percentile crossing | Crossing 2 or more major percentile lines (5th, 10th, 25th, 50th, 75th, 95th) | Initiate growth management hierarchy |
| Z-score shift | Greater than 0.5 SD decline in one year | Same as above |
| Weight velocity | Z-score decline >0.5 SD in 6 months | Dietary optimization; caloric supplementation |
| Predicted adult height | Projected >1.5 SD below mid-parental height | Specialist referral for endocrine assessment |
| BMI centile | Crossing from normal to underweight | Nutritional assessment; consider drug holiday or class switch |
Growth Management Hierarchy (least invasive first):
- Dietary optimization: Calorie-dense breakfast before medication; high-calorie "fourth meal" at 8 PM when medication wears off; focus on caloric density not volume (olive oil, whole milk, protein powder)
- Drug holidays: Weekend holidays for weight/appetite. Summer holidays (8-12 weeks) for height catch-up
- Switch formulations or class: Amphetamines cause greater growth suppression than MPH. Alpha-2 agonists are weight-neutral
- Specialist referral: If height velocity remains below 4 cm/year despite above interventions, or height falls below 3rd percentile, refer to pediatric endocrinology
4. Cardiovascular Parameters
HR and BP at every visit. For children, compare against age/sex/height-specific centile charts.
Clinical decision thresholds:
| Finding | Action |
|---|---|
| BP consistently at or above 95th percentile (children) or 140/90 (adults) | Consider reducing dose or switching to non-stimulant. However, if the stimulant is the only medication providing adequate ADHD control and the clinical benefit is substantial, treating the elevated BP with an antihypertensive (e.g., an alpha-2 agonist, which has the added benefit of augmenting ADHD treatment) may be preferable to removing effective ADHD treatment |
| Resting HR persistently elevated (>100 bpm adults, or above age-adjusted norms) | Consider reducing dose or switching to non-stimulant. Same principle applies: if the stimulant is uniquely effective, managing the cardiovascular parameter pharmacologically is a reasonable clinical choice |
Long-term cardiovascular context: Swedish registry data (Zhang et al., 2023, JAMA Psychiatry): longer cumulative ADHD medication use associated with increased hypertension risk (adjusted OR 1.72 for 3-5 years of cumulative use). Cardiovascular monitoring is a lifetime commitment for patients on chronic ADHD medication.
5. Functional Assessment
The domain most commonly omitted and the one that matters most. Symptoms can improve while functioning does not (the symptom-function gap).
| Domain | What to Assess | Tool |
|---|---|---|
| Academic (children) | Are grades improving, or only behavior? Medication improves on-task behavior but does not teach skills never acquired | WFIRS School/Learning subscale; report cards; IEP progress notes |
| Social (all ages) | Friendship quality, peer conflict, relationship stability. Least responsive to medication alone | WFIRS Social Activities subscale |
| Family (all ages) | Parent-child conflict frequency, sibling relationships, parental mental health (including untreated parental ADHD) | WFIRS Family subscale |
| Occupational (adults) | Workplace performance, punctuality, task completion, employment retention | WFIRS Self/Work subscale |
| Emotional regulation | Frustration tolerance, outburst intensity, mood variability. Among earliest indicators of medication wearing off or dose insufficiency | Brief question: "How are the emotional outbursts compared to last time?" |
| Self-concept | Internalized shame from years of underperformance. Persists even after symptoms improve | WFIRS Self-Concept subscale. When self-concept remains low despite remission, the need is for therapy, not dose increase |
| Driving safety (age 16+) | Traffic violations, near-misses, medication coverage during typical driving times | Stimulant medication reduces crash risk 38–58% in males, 27–42% in females (Chang et al., 2014 Swedish registry [58% in males]; Chang et al., 2017 US cohort [38% in males, 42% in females], JAMA Psychiatry). Female protective effect significant only in the US cohort. Discuss driving explicitly when considering drug holidays |
The WFIRS (Weiss Functional Impairment Rating Scale) is the gold standard for functional monitoring. Available free through the CADDRA toolkit (caddra.ca). Covers 6 domains: Family, School/Work, Life Skills, Self-Concept, Social Activities, Risk-Taking. Administer at baseline and every 3-6 months.
Defining Treatment Success
Response vs. Remission
| Category | Definition | Psychometric Threshold | Clinical Significance |
|---|---|---|---|
| Response | 30% or more reduction from baseline on ADHD-RS | Minimum threshold for clinically meaningful change | Patient is better, but may still be symptomatic |
| Optimal response | 50-60% or more reduction; CGI-I = 1 ("Very Much Improved") | Target for medication titration | Corresponds to normalization of daily functioning in many patients |
| Remission | ADHD-RS total score 18 or below | Symptom levels within normative population range | Patient is well, not just better. This should be the ultimate therapeutic target (Faraone et al., 2021) |
| Functional remission | Symptom remission PLUS normal-range WFIRS scores | Rare in practice without combined treatment | True treatment success; requires medication + skills-based intervention |
The "Good Enough" Debate: Aim for remission whenever possible. Accept "functional success with residual symptoms" when dose increases produce intolerable side effects or when the patient, fully informed of trade-offs, prefers the current balance. Residual symptoms are predictors of future comorbidity and treatment discontinuation.
The Two-Question Treatment Check
At every maintenance visit:
- "What does the rating scale score say?" (Symptom status with a number, not a feeling)
- "Is this person functioning well in school/work, relationships, and daily life?" (Functional status)
| Symptoms | Functioning | Interpretation | Action |
|---|---|---|---|
| Remission | Good | Treatment optimized | Maintain current plan |
| Remission | Poor | Symptom-function gap | Skills deficit, not medication problem. Refer for ADHD-adapted CBT or executive function coaching |
| Elevated | Poor | Inadequate treatment | Medication needs adjustment |
| Elevated | Good | Investigate | Rating scale may not be capturing the right picture (informant bias, setting-specific symptoms) |
Troubleshooting Inadequate Response: The DATER Framework
Before switching medications, run through CADDRA's DATER checklist (CADDRA 4th Ed., 2020):
| Letter | Question | Common Finding |
|---|---|---|
| D - Dose | Was the dose optimized? Did you titrate to maximum tolerated dose, or settle at the first dose that showed improvement? | Under-dosing is one of the most common prescribing errors |
| A - All | Have all options within the current drug class been tried? Different formulations have different PK profiles and may produce different clinical responses | Switching formulations within class is an underutilized strategy |
| T - Time | Was the trial duration sufficient? Stimulants: 1-2 weeks per dose level. Atomoxetine: 6-8 weeks at target dose. Alpha-2 agonists: 4-6 weeks | Premature switching is common |
| E - Expectations | Were treatment goals realistic? Medication resolves symptoms, not accumulated skill deficits | The symptom-function gap (see above) |
| R - Review | Is the diagnosis correct? Has anything changed since the initial evaluation? | Undiagnosed comorbidity (anxiety, LD, sleep disorder, trauma) is the most common driver of apparent treatment resistance |
Pseudo-Resistance: The Usual Suspects
Most "treatment failure" is not pharmacological resistance. Check these first:
| Suspect | How to Detect | How to Address |
|---|---|---|
| Non-adherence | Ask non-judgmentally: "How many doses missed in past 2 weeks?" Check PDMP for fill patterns. Adherence ~64% at 1 year (EAGG, 2024); <25% maintain consistent daily adherence | Simplify regimen (QD > BID), address barriers (forgetting, side effects, stigma, cost), medication reminders |
| Coverage gaps | Child unmedicated during homework/sports/social hours (e.g., ER wears off at 3 PM but demands extend to 8 PM) | Add afternoon IR booster (same class, typically half the ER dose) or switch to longer-duration formulation. Do not increase morning dose |
| Rebound | Temporary, intense symptom flare-up as medication wears off, often worse than unmedicated baseline. Occurs daily on predictable schedule | Smooth the decline: add small booster dose or switch to gentler wear-off formulation. This is a PK problem, not treatment failure |
| Undetected comorbidity | Anxiety, sleep disorders, learning disabilities, depression emerged or was missed | Reassess with broadband screening. A Vanderbilt negative for internalizing does NOT rule out anxiety (sensitivity ~0.37) |
| Diagnostic error | Symptoms driven by trauma, sleep apnea, thyroid, iron deficiency | Re-evaluate with Module 2 differential diagnosis framework |
The Two-Drug Rule: Do NOT label a patient "treatment resistant" until they have had adequate trials of both methylphenidate AND amphetamine classes. Different presynaptic mechanisms. Cumulative response rate when both classes trialed sequentially: 87-91% (Hodgkins et al., 2012).
Medication Discontinuation
When to Consider a Trial
After sustained stability (6-12 months), timed to lower-demand period (summer break, quieter work period), with reliable observers available. Not during major life transitions.
Discontinuation Protocols by Drug Class
| Drug Class | Withdrawal Risk | Taper Protocol | Symptom Return Timeline |
|---|---|---|---|
| Methylphenidate | LOW: no physiological withdrawal | Can stop abruptly; gradual reduction preferred (1-2 weeks to mitigate rebound irritability) | 24-48 hours |
| Amphetamine | LOW: no physiological withdrawal; mild fatigue possible | Can stop abruptly; gradual reduction preferred | 24-48 hours |
| Atomoxetine | LOW-MODERATE: discontinuation symptoms rare but reported | Taper over 1-2 weeks recommended | 1-2 weeks (longer half-life) |
| Alpha-2 agonists | HIGH: rebound hypertension risk | MANDATORY taper. Guanfacine: reduce by 1 mg every 3-7 days. Clonidine: reduce by 0.05-0.1 mg every 3-7 days. Monitor BP during taper | N/A (taper to zero) |
| Viloxazine | LOW: limited long-term discontinuation data | Taper over 1 week recommended (SNRI class) | Days to weeks |
Relapse Rates
Adults who stop medication: ~3.7x more likely to relapse vs. continuation (Tsujii et al., 2020). Children/adolescents: ~2.4x more likely. These are enrichment-design estimates (study population excludes non-responders). The majority of patients relapse upon discontinuation.
Rebound vs. Relapse
| Feature | Rebound | Relapse |
|---|---|---|
| What it is | PK event: temporary symptom flare as medication wears off | Clinical event: sustained return to baseline impairment |
| Timeline | Daily, predictable (3-4 hrs after IR, 8-12 hrs after ER) | Days to weeks after discontinuation; persistent |
| Severity | Often worse than unmedicated baseline | Returns to unmedicated baseline |
| Management | Smooth the decline (add booster, switch formulation) | Resume medication or intensify non-pharmacological support |
The Annual Comprehensive Review
NICE mandates a structured annual review covering:
- Clinical need: Is the medication still required?
- Adherence patterns: Signs of missed doses or irregular use?
- Detailed side effect inquiry: Sleep, appetite, mood, cardiovascular symptoms
- Functional impact: Education/employment, social functioning, family relationships
- Patient/family preference: Continuing treatment?
- Growth trajectory review (pediatric): Plot full-year growth on chart
- Cardiovascular trend review: BP/HR trend over the year
- Consider discontinuation trial: If stable 6-12 months, is a supervised trial appropriate?
This review safeguards against "prescribing inertia," the tendency for patients to remain on medications for years without re-evaluation.
The Pediatric-to-Adult Transition (Ages 16-25)
The single highest-risk period for treatment discontinuation and loss to follow-up.
Transition checklist (initiate at least 1 year before expected handoff):
- Identify an adult provider before the transition date
- Prepare clinical summary: current regimen, medication history (what was tried, what failed, why), comorbidities, monitoring baseline
- Discuss self-advocacy skills: scheduling appointments, communicating side effects, managing refills independently
- Address the "I don't need it anymore" phase: use fluctuating course data (~64% follow a relapsing-remitting pattern, not stable remission) to frame this as a decision to make with data, not a default
Long-Term Prognosis: Key Numbers for Clinical Conversations
| Finding | Data | Source |
|---|---|---|
| Fluctuating course | ~64% oscillate between meeting criteria and sub-threshold functioning. 60% of those who appeared remitted at one timepoint eventually recurred | Sibley et al. (2022) Am J Psychiatry |
| Stable remission | ~10% achieve sustained, complete remission | Sibley et al. (2022) |
| Stable persistence | ~10% consistently meet full criteria (high baseline severity, significant comorbidity) | Sibley et al. (2022) |
| Mortality protection | Medication initiation within 3 months of diagnosis: 21% lower all-cause mortality (HR 0.79), 25% reduction in unnatural-cause deaths (HR 0.75) | Li et al. (2024) JAMA |
| Protective effects during treatment | Reduced suicide attempts (RR 0.83), substance misuse (RR 0.85), criminality (RR 0.87), transport accidents (RR 0.88) | Zhang et al. (2025) BMJ |
Non-Prescriber Monitoring Roles
For school psychologists, LCSWs, LMFTs, and other non-prescribing clinicians:
| Role | What You Can Monitor | Action When Concerns Arise |
|---|---|---|
| School psychologists | Academic functioning longitudinally, accommodation appropriateness, teacher-reported symptoms vs. parent reports | Flag to prescriber when academic trajectory stalls despite reported symptom improvement |
| Therapists (CBT/skills-based) | Symptom-function gap (is it closing?), emotional blunting emerging in session, new comorbidity (depressive cognitions), adherence drift (client mentions skipping doses) | Proactively communicate observations to prescriber rather than waiting for next prescriber visit |
| All non-prescribers | Weekly therapy sessions are often the highest-frequency monitoring contact (4-8x more frequent than prescriber visits). Use same instruments (Vanderbilt, WFIRS) to create shared monitoring language | Document observations using validated instruments to support clinical communication |
This quick reference tool is extracted from Module 9: Monitoring, Adjusting & Long-Term Management. For the full monitoring framework, growth monitoring detail, cardiovascular evidence review, discontinuation protocols, and complete references, see the full clinical module.
For the full clinical curriculum, visit psychhq.com
Key References: AAP Clinical Practice Guideline (2019) Pediatrics; NICE NG87 (2018/2024); CADDRA 4th Ed. (2020); MTA Cooperative Group (1999, 2004); Sibley et al. (2022) Am J Psychiatry; Zhang et al. (2025) BMJ; Li et al. (2024) JAMA; Faraone et al. (2021) Neurosci Biobehav Rev; Ferrin et al. [EAGG] (2024) Eur Child Adolesc Psychiatry